Informations générales (source: ClinicalTrials.gov)
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Interventional
Phase 2/Phase 3
Celgene (Voir sur ClinicalTrials)
juillet 2018
novembre 2036
02 février 2026
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for
all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy
participating in a previous Celgene sponsored or Celgene alliance partner sponsored
study.
Participants who received at least one infusion of GM T cells will be asked to enroll in
this LTFU protocol upon either premature discontinuation from, or completion of the prior
parent treatment protocol.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Vincent RIBRAG | 10/06/2024 12:26:35 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Henri Mondor-Albert Chenevier | Karim BELHADJ-MERZOUG, Site 09211 | Contact (sur clinicalTrials) | |||
Critères
Tous
- Received at least one gene-modified (GM) T-cell infusion in a previous Celgene
sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance
partner-sponsored trial, and have discontinued, or completed the post-treatment
follow-up period in the parent treatment protocol, as applicable.
- Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form
prior to any study-related assessments/procedures being conducted.
Exclusion Criteria:
Not Applicable
Other protocol-defined inclusion/exclusion criteria apply